00840cam0 2200253 450 E60020004926420210915063453.020090520d1982 |||||ita|0103 baitaFRPaul ClaudelParisEuropeMessidor-Temps Actuels1982264 p.22 cm.EuropeRevue littéraire mensuelle60 année001LAEC000183142001 *Europe : Revue littéraire mensuelle60 annéeITUNISOB20210915RICAUNISOBUNISOB840|Coll|11|K34898E600200049264M 102 Monografia moderna SBNM840|Coll|11|K000010Si34898acquistopregresso2UNISOBUNISOB20090520111150.020160121150817.0AlfanoPaul Claudel553974UNISOB04853nam 2200853Ia 450 991095894730332120251017110114.09786611767525978030918569103091856969781281767523128176752297803091186750309118670(CKB)2550000000004405(EBL)3378374(SSID)ssj0000288925(PQKBManifestationID)11220286(PQKBTitleCode)TC0000288925(PQKBWorkID)10383139(PQKB)10130252(MiAaPQ)EBC3378374(Au-PeEL)EBL3378374(CaPaEBR)ebr10237094(CaONFJC)MIL176752(OCoLC)923279005(Perlego)4740388(DNLM)1480731(BIP)21074671(EXLCZ)99255000000000440520080521d2008 uy 0engur|n|---|||||txtccrAntivirals for pandemic influenza guidance on developing a distribution and dispensing program /Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies1st ed.Washington, DC National Academies Pressc20081 online resource (x, 122 pages)Description based upon print version of record.Print version: Institute of Medicine (U.S.). Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic. Antivirals for pandemic influenza. Washington, DC : National Academies Press, ©2008 9780309118668 (DLC) 2008298577 (OCoLC)228498016 9780309118668 0309118662 Includes bibliographical references.Introduction -- Antiviral effectiveness, safety, and supply -- Ethics, decision making, and communication -- Who should get antivirals and where?Planning for an influenza pandemic, whether it occurs in the near or distant future, will need to take into account many constantly evolving factors. The Institute of Medicine (IOM) Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic was asked by the Department of Health and Human Services, (DHHS) to consider best practices and policies for providing antiviral treatment and prophylaxis during a pandemic event. The committee (TM)s report, entitled Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program, calls for a national and public process of creating an ethical framework for antiviral use within the context of uncertainty and scarcity. It is unclear whether antivirals will work against a pandemic strain as well as they work against seasonal influenza. Also, government stockpiles may not be sufficient for all possible uses in part because antivirals are costly and public health agencies must invest in other important activities, including other medical resources for pandemic influenza. Furthermore, the report identifies the lack of a science-based advisory body to guide decision making during the pandemic, including guidance on all dimensions of antiviral dispensing (for example, prioritization, drug safety, and antiviral resistance). The report also acknowledges the need for diverse methods and sites of dispensing, and discusses their advantages and disadvantages.Antiviral agentsEffectivenessAntiviral agentsEpidemicsPreventionInfluenzaPreventionInfluenza, Humanprevention & control(DNLM)D007251Q000517Antiviral Agentssupply & distribution(DNLM)D000998Q000600Program Developmentmethods(DNLM)D016730Q000379Antiviral Agentstherapeutic use(DNLM)D000998Q000627Disease Outbreaksprevention & control(DNLM)D004196Q000517Antiviral agentsEffectiveness.Antiviral agents.EpidemicsPrevention.InfluenzaPrevention.Influenza, Humanprevention & control.Antiviral Agentssupply & distribution.Program Developmentmethods.Antiviral Agentstherapeutic use.Disease Outbreaksprevention & control.614.518Institute of Medicine (U.S.).Board on Population Health and Public Health Practice.MiAaPQMiAaPQMiAaPQBOOK9910958947303321Antivirals for pandemic influenza4365666UNINA